| Autor: |
Grzymski JJ; Renown Health, Reno, NV, USA. joe.grzymski@dri.edu.; Desert Research Institute, Reno, NV, USA. joe.grzymski@dri.edu., Elhanan G; Desert Research Institute, Reno, NV, USA., Morales Rosado JA; Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA., Smith E; Desert Research Institute, Reno, NV, USA., Schlauch KA; Desert Research Institute, Reno, NV, USA., Read R; Desert Research Institute, Reno, NV, USA., Rowan C; Renown Health, Reno, NV, USA., Slotnick N; Renown Health, Reno, NV, USA., Dabe S; Desert Research Institute, Reno, NV, USA., Metcalf WJ; Desert Research Institute, Reno, NV, USA., Lipp B; Desert Research Institute, Reno, NV, USA., Reed H; Desert Research Institute, Reno, NV, USA., Sharma L; Helix, San Mateo, CA, USA., Levin E; Helix, San Mateo, CA, USA., Kao J; Helix, San Mateo, CA, USA., Rashkin M; Helix, San Mateo, CA, USA., Bowes J; Helix, San Mateo, CA, USA., Dunaway K; Helix, San Mateo, CA, USA., Slonim A; Renown Health, Reno, NV, USA., Washington N; Helix, San Mateo, CA, USA., Ferber M; Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA., Bolze A; Helix, San Mateo, CA, USA., Lu JT; Helix, San Mateo, CA, USA. james.lu@helix.com. |
| Abstrakt: |
Three inherited autosomal dominant conditions-BRCA-related hereditary breast and ovarian cancer (HBOC), Lynch syndrome (LS) and familial hypercholesterolemia (FH)-have been termed the Centers for Disease Control and Prevention Tier 1 (CDCT1) genetic conditions, for which early identification and intervention have a meaningful potential for clinical actionability and a positive impact on public health 1 . In typical medical practice, genetic testing for these conditions is based on personal or family history, ethnic background or other demographic characteristics 2 . In this study of a cohort of 26,906 participants in the Healthy Nevada Project (HNP), we first evaluated whether population screening could efficiently identify carriers of these genetic conditions and, second, we evaluated the impact of genetic risk on health outcomes for these participants. We found a 1.33% combined carrier rate for pathogenic and likely pathogenic (P/LP) genetic variants for HBOC, LS and FH. Of these carriers, 21.9% of participants had clinically relevant disease, among whom 70% had been diagnosed with relevant disease before age 65. Moreover, 90% of the risk carriers had not been previously identified, and less than 19.8% of these had documentation in their medical records of inherited genetic disease risk, including family history. In a direct follow-up survey with all carriers, only 25.2% of individuals reported a family history of relevant disease. Our experience with the HNP suggests that genetic screening in patients could identify at-risk carriers, who would not be otherwise identified in routine care. |
Full text from SpringerLink